Patient

Programs

Information For Patients And Families

Patients’ needs drive our relentless pursuit of groundbreaking science.
patient-program-img01
Image of Circles

Diseases Our Programs Support

References
1.
National Institutes of Health. Accessed September 26, 2022. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.
2.
American Society of Clinical Oncology Publications. Accessed September 26, 2022. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
3.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq.
4.
Cancer.Net. Accessed January 12, 2023. https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics.
5.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq#:~:text=Myelodysplastic%20syndromes%20are%20a%20group,blood%20cells%20and%20bone%20marrow.
6.
Tricot GJ, Lauer RC, Appelbaum FR, et al. Management of the myelodysplastic syndromes. Semin Oncol. 1987;14(4):444-53. [PUBMED Abstract]
 
 

Hear From Paul, a Patient, on Finding a Cullinan Therapeutics Clinical Trial

Why patients and clinical trials matter
We are grateful to every patient who participates in a clinical trial to help advance our collective understanding of disease and how new medicines work. At Cullinan Therapeutics, we are committed to creating safer, more effective treatments for patients. Without patients participating in clinical trials, we wouldn’t be able to meet that commitment.
 

Harnessing Science for Patient Benefit

Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.